MASH Drug Development 2025: Clinical vs Preclinical Data
MASH therapeutics post-Resmetirom: Phase 2/3 data vs. GAN DIO-MASH models for Semaglutide, Lanifibranor, Efruxifermin, and future Lean MASH strategies.
1. Introduction: The Paradigm Shift in MASH Drug Development
Evolution of the Disease Concept and Unmet Medical Needs
The disease formerly known as Non-Alcoholic Steatohepatitis (NASH) has recently been renamed to Metabolic dysfunction-associated Steatohepatitis (MASH) to more accurately reflect its pathophysiological essence. This change is more than a mere terminology update; it emphasizes that the accumulation of metabolic factors such as obesity, type 2 diabetes, and dyslipidemia is deeply involved in the progression of liver pathology. This shift has broadened the target of drug development to systemic metabolic improvement.
MASH is a chronic, progressive disease that advances from simple steatosis to hepatocellular ballooning, inflammation, and ultimately fibrosis. It is well established that patients, especially those with moderate (F2) and severe (F3) fibrosis stages, face a dramatically increased risk of liver-related mortality.
In this field, often referred to as a "valley of death" where no pharmacological therapies existed for decades, 2024 marked a historic turning point. The approval of Resmetirom by the US FDA became the first success story in MASH treatment, accelerating subsequent drug development.
[!NOTE] Purpose of this Article This article provides a comprehensive comparison and analysis of clinical trial results and preclinical data for the approved drug Resmetirom and promising compounds currently in late-stage clinical development (Semaglutide, Lanifibranor, Efruxifermin, Denifanstat, etc.). We will explore how mechanisms in preclinical models can predict clinical outcomes and outline the formation of future Standards of Care (SoC), including strategies for "Lean MASH," a phenotype common in Asian populations.
2. In-Depth Analysis of the Approved Drug Resmetirom (THR-β Agonist)
Resmetirom (Brand name: Rezdiffra) was the world's first drug approved by the FDA in March 2024 for the treatment of "adult patients with noncirrhotic MASH with moderate to advanced liver fibrosis (F2-F3)."
Mechanism of Action (MOA): Establishing Safety via Liver Selectivity
Resmetirom is an oral, selective agonist for the Thyroid Hormone Receptor beta (THR-β).
- THR-β: Highly expressed in the liver, regulating lipid metabolism and mitochondrial function.
- THR-α: Distributed in the heart and bones; overstimulation poses risks of tachycardia and osteoporosis.
Resmetirom boasts approximately 28-fold selectivity for THR-β over THR-α, allowing it to exert T3-like effects (promoting mitochondrial β-oxidation, suppressing de novo lipogenesis) exclusively within the liver while avoiding cardiac and skeletal side effects.
Phase 3 MAESTRO-NASH Trial: Details of the Historic Data
The Phase 3 trial (biopsy data at 52 weeks), which served as the basis for FDA approval, achieved statistically significant differences in both surrogate endpoints proposed by the FDA—making it the first trial in history to do so.
Trial Information: MAESTRO-NASH (NCT03900429)
| Endpoint | Placebo (n=321) | Resmetirom 80mg (n=322) | Resmetirom 100mg (n=323) | P-Value |
|---|---|---|---|---|
| MASH Resolution (no worsening of fibrosis) | 9.7% | 25.9% | 29.9% | < 0.0001 |
| Fibrosis Improvement (≥1 stage & no NAS worsening) | 14.2% | 24.2% | 25.9% | < 0.0001 |
| LDL-C Change (24 weeks) | +0.1% | -13.6% | -16.3% | < 0.0001 |
- MASH Resolution: Response rate approximately 3 times that of placebo. Inflammation and ballooning were resolved.
- Fibrosis Improvement: Improvement was confirmed even in advanced cases such as F3 (severe fibrosis).
- Safety: Primary side effects were diarrhea and nausea (mild to moderate). No severe hepatotoxicity signals.
High Translation with Preclinical Data
The successful development of Resmetirom is backed by robust evidence from preclinical studies. Data from models like the GAN DIO-MASH mouse model highly predicted the eventual clinical outcomes.
- Liver Steatosis and Inflammation: Reductions in hepatic triglycerides and suppression of inflammatory cytokines (TNF-α, MCP-1) in mice correlated with MRI-PDFF reductions (-30% to -50%) in clinical human trials.
- Fibrosis Repair: Preclinical data suggested that the repair was a secondary promotion of "hepatocyte recovery" resulting from the relief of lipotoxicity and inflammation, rather than a direct anti-fibrotic effect. This aligns perfectly with the clinical results where MASH resolution and fibrosis improvement occurred in parallel.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
3. The Next-Generation Frontrunners: Incretin-Based Therapies
Incretin-based therapies, primarily GLP-1 receptor agonists, represent the "metabolic improvement approach" that ameliorates MASH through potent weight loss effects.
Semaglutide (GLP-1): Overwhelming MASH Resolution Rates
Novo Nordisk's Semaglutide demonstrated dramatic histological improvements surpassing Resmetirom in the Phase 3 ESSENCE trial.
Trial Information: ESSENCE (NCT04822181)
ESSENCE Part 1 (F2-F3 MASH, 72 weeks) Results Summary
- MASH Resolution: Semaglutide 2.4mg 62.9% vs Placebo 34.1%
- Fibrosis Improvement: Semaglutide 2.4mg 37.0% vs Placebo 22.5%
- Weight Loss: Semaglutide -10.5% vs Placebo -2.0%
The 62.9% MASH resolution rate is overwhelming, proving that profound weight loss directly translates to improvements in liver pathology. Preclinically, in addition to indirect effects via caloric restriction, direct effects such as De Novo Lipogenesis (DNL) reduction via PI3K/AKT/mTORC1 pathway suppression have also been suggested.
Tirzepatide & Survodutide: The Power of Dual Agonists
Dual agonists, which possess even stronger metabolic improvement effects, have also produced astonishing data.
| Drug Name | Mechanism | Trial (NCT) | MASH Resolution | Fibrosis Improvement | Features |
|---|---|---|---|---|---|
| Tirzepatide | GLP-1/GIP | SYNERGY-NASH (Ph2b, 52w) | 73.3% (15mg) | 54.2% | Maximum class weight loss and MASH resolution. Ph3 in preparation. |
| Survodutide | GLP-1/Glucagon | Ph2 MASH (48w, NEJM 2024) | 47-62% | 34-36% (ITT) 64.5% (F2-F3 post-hoc) | Increased energy expenditure via glucagon. LIVERAGE Ph3 + Cirrhosis Ph3 ongoing. See Survodutide deep-dive. |
4. Direct Approaches to Fibrosis: FGF21 & PPAR & FASN
Unlike incretins, drug classes that act more directly on liver fibrosis and inflammation are critical for patients with advanced fibrosis (F3-F4) or those who do not necessarily require massive weight loss.
Efruxifermin (FGF21): Hopes for Cirrhosis "Reversal"
Efruxifermin, an FGF21 analog, has shown exceptionally high fibrosis improvement rates with long-term administration. In December 2025, Novo Nordisk completed acquisition of Akero Therapeutics for up to $5.2B. See the Efruxifermin deep-dive for details.
- HARMONY Trial (Ph2b) [NCT04767529]: 49% achieved fibrosis improvement at 96 weeks (F2-F3; placebo 19%). The Lancet 2025.
- SYMMETRY Trial (F4 Cirrhosis) [NCT05039450]: Even in cirrhotic patients, fibrosis reversal was confirmed at 96 weeks (39% vs 15%), opening up possibilities for treating cirrhosis previously considered irreversible (N Engl J Med 2025, PMID 40341827).
- Current Status: Ph3 SYNCHRONY programme — three trials (Histology NCT06215716 / Real-World NCT06161571 / Outcomes NCT06528314) — is ongoing (2026-2027 readout).
Lanifibranor (Pan-PPAR): Omnidirectional Liver Protection
A Pan-PPAR agonist that simultaneously activates PPARα/δ/γ.
- NATIVE Trial (Ph2b) [NCT03008070]: The only oral drug to achieve the composite endpoint of "MASH Resolution" AND "Fibrosis Improvement."
- NATiV3 Trial (Ph3) [NCT04849728]: Targets F2-F3 patients; enrollment of 1,009 patients complete. Topline results expected late 2026.
- Features: In mouse models (GAN DIO-NASH), it is one of the few drugs to clearly demonstrate regression of fibrosis stages, indicating potent direct anti-fibrotic action. Development in Japan is also underway (Ph1 initiated by Hepalys Pharma).
Denifanstat (FASN Inhibitor): Direct Blockade of Lipogenesis
Blocks De Novo Lipogenesis (DNL) at the rate-limiting enzyme level.
- FASCINATE-2 Trial (Ph2b) [NCT05976230]: 52 weeks, F2-F3 patients. Fibrosis improvement rate 30% (ITT) / 41% (mITT) vs Placebo 14% / 18%. Highly effective in F3 patients with a Number Needed to Treat (NNT) of 4-6.
- Ph3 Transition: Granted FDA Breakthrough Therapy designation.
- Features: Oral drug. Possessing a mechanism distinct from Resmetirom, it is highly anticipated as a combination therapy partner.
5. Integrated Comparison of Clinical Data and Preclinical Models
Below is a comparative summary of major clinical trial data and the underlying preclinical mechanisms supporting them.
Clinical Data Comparison Summary of Major Drugs (Phase 2b/3)
The following table summarizes the achievement rates of primary endpoints in placebo-controlled trials for each drug. Note that this is not a head-to-head comparison, as trial designs and patient populations differ.
| Drug (Class) | Trial (NCT) | MASH Resolution Rate (Active vs PBO) | Fibrosis Improvement Rate (Active vs PBO) | Key Preclinical Findings |
|---|---|---|---|---|
| Resmetirom (THR-β) | MAESTRO-NASH | ~30% vs 10% | ~26% vs 14% | Massive improvement in liver fat/inflammation precedes fibrosis improvement in GAN DIO-MASH. |
| Semaglutide (GLP-1) | ESSENCE | ~63% vs 34% | ~37% vs 23% | Dramatic liver fat clearance dependent on weight loss. Fibrosis regression in models is moderate. |
| Tirzepatide (GLP-1/GIP) | SYNERGY-NASH | ~73% vs 13% | ~54% vs 33% | Maximum metabolic improvement. Exceptional fat reduction in models. |
| Survodutide (GLP-1/Glucagon) | Ph2 MASH (NEJM 2024) | 47-62% vs 14% | 34-36% (ITT) / 64.5% (F2-F3 post-hoc) vs 25.9% | Potent anti-fibrotic signaling driven by glucagon agonism. |
| Efruxifermin (FGF21) | HARMONY | ~62% vs 24% | 49% vs 19% (96w extension) | Confirmed strong direct anti-fibrotic action beyond weight loss effects. |
| Lanifibranor (Pan-PPAR) | NATIVE | ~49% vs 22% | ~48% vs 29% | Clear fibrosis stage regression in models, aligning with high clinical fibrosis improvement rates. |
| Denifanstat (FASN) | FASCINATE-2 | ~36% vs 13% | ~41% vs 18% | Direct lipotoxicity relief via DNL inhibition. Effective against F3 fibrosis. |
Insights from Preclinical Models
- Utility of the GAN DIO-MASH Model: The GAN DIO-MASH mouse, considered a modern standard model, accurately replicates biopsy-confirmed NASH, progressive fibrosis, and progression to HCC. It predicted the clinical efficacy of Resmetirom and Lanifibranor with high clinical translation accuracy.
- Mechanistic Differences: GLP-1 therapies exhibit a "fat disappearance-first" behavior, whereas Lanifibranor and Efruxifermin display a "fibrosis-parallel/first" behavior. This aligns with clinical observations where GLP-1s hold an overwhelming advantage in MASH resolution (fat/inflammation), while FGF21 and PPAR agonists surpass them in numerical fibrosis improvement rates.
6. The "Lean MASH" Prospect and Development in Asia
While many MASH patients in the US and Europe are severely obese with a BMI over 30, approximately 20-30% of patients in Asia, including Japan, develop the disease with a BMI under 25, known as "Lean MASH".
- The Challenge: Potent weight-loss drugs like Semaglutide and Tirzepatide may pose risks of muscle mass reduction (sarcopenia) in lean patients and might be unsuitable for this demographic.
- The Solution: The need for drugs that do not rely on systemic weight loss—such as Resmetirom (THR-β), Lanifibranor (PPAR), and Denifanstat (FASN)—is arguably higher in Asia than in Western countries. Resmetirom, in particular, has a neutral effect on boy weight, making it an essential option in future clinical settings in these regions.
7. Conclusion and Future Perspectives: The Era of Combination Therapies and NITs
MASH treatment has taken its first steps toward becoming a "manageable disease" with the advent of Resmetirom. Looking ahead, three key areas will define the landscape:
- Treatment Stratification (Precision Medicine):
- Obesity/Diabetes Comorbidity → Incretins (Semaglutide, Tirzepatide)
- Advanced Fibrosis (F3-F4) / Non-Obese → Liver Targets (Resmetirom, Efruxifermin, Lanifibranor)
- Advancement of Combination Therapies: Combining "systemic metabolic improvement" (GLP-1) with "direct liver action" (THR-β/FASN), such as Semaglutide + Resmetirom, is likely to become the next standard of care aiming for deeper remission and fibrosis reversal.
- Establishment of Non-Invasive Tests (NITs): The widespread adoption of MRI-PDFF and blood biomarkers (FIB-4, ELF, Mac-2bpGi) as alternatives to liver biopsy will exponentially improve treatment access in real-world clinical practice.
[!TIP] For Researchers and Developers Our CRO provides comprehensive preclinical contract research services, featuring optimal models for MASH drug development such as the GAN DIO-MASH mouse. We offer end-to-end support, from selecting the ideal model tailored to your compound's mechanism to biomarker analysis and histological evaluation.
Learn more about Preclinical MASH Models
Learn more about Fibrosis Assessment Technologies
Appendix: Comprehensive MASH Therapeutics Data Analysis
Table 1: Approved and Phase 3 MASH Therapeutics
| Drug Name | Brand Name | Mechanism of Action | Approval Status (JP/US/EU) | Clinical Trials & Features |
|---|---|---|---|---|
| Resmetirom | Rezdiffra | THR-β Selective Agonist | Unapproved / Approved (2024.3) / Approved | MAESTRO-NASH [NCT03900429] World's first approved MASH drug. Targets F2-F3. |
| Semaglutide | Wegovy/Ozempic | GLP-1 Receptor Agonist | Approved (Obesity) / Approved (Obesity) / Approved | ESSENCE [NCT04822181] MASH resolution 62.9%. Preparing for US/EU regulatory submission. |
Table 2: Pipeline of Promising Phase 2/3 Clinical Trials
| Phase | Drug Name (Code) | Mechanism/Target | Clinical Trial Links | Clinical Summary & Key Results |
|---|---|---|---|---|
| Ph3 | Semaglutide | GLP-1 Receptor Agonist | NCT04822181 (ESSENCE) | ESSENCE Ph3: MASH resolution 62.9% vs 34.1%. Fibrosis improvement 36.8% vs 22.4%. Weight -10.5%. |
| Ph3 Prep | Tirzepatide | GLP-1/GIP Dual Agonist | NCT04166773 (SYNERGY-NASH) | SYNERGY-NASH Ph2b: MASH resolution 73.3% in 15mg group. Highest response rate to date. |
| Ph3 | Survodutide | GLP-1/Glucagon Dual | NCT04771273 (Ph2 MASH) NCT06632444 (LIVERAGE) NCT06632457 (LIVERAGE-Cirrhosis) | Ph2 (NEJM 2024): Fibrosis improvement 64.5% vs 25.9% (F2-F3 post-hoc). FDA Breakthrough 2024/10. See Survodutide deep-dive. |
| Ph3 | Efruxifermin (EFX) | FGF21 Analog | NCT04767529 (HARMONY) NCT05039450 (SYMMETRY) NCT06215716 (SYNCHRONY Histology) NCT06528314 (SYNCHRONY Outcomes) | HARMONY Ph2b: Fibrosis improvement 49% at 96 weeks (Lancet 2025). SYMMETRY: 39% F4 reversal (NEJM 2025). Novo Nordisk acquisition completed Dec 2025. See Efruxifermin deep-dive. |
| Ph3 | Lanifibranor | Pan-PPAR (α/δ/γ) | NCT03008070 (NATIVE) NCT04849728 (NATiV3) | NATIVE Ph2b: Achieved composite of MASH resolution + fibrosis improvement. NATiV3 Ph3: 1,009 patients enrolled, results late 2026. Ph1 ongoing in Japan. |
| Ph3 Prep | Denifanstat | FASN Inhibitor | NCT05976230 (FASCINATE-2) | FASCINATE-2 Ph2b: Fibrosis improvement 41% (mITT) vs 18%. NNT=4-6. Highly effective for F3. |
| Ph3 Prep | Pegozafermin (PEG-FGF21) | FGF21 Analog (PEGylated) | NCT05006885 (ENLIVEN) NCT05931887 (ENLIGHTEN-Fibrosis) | ENLIVEN Ph2b: Fibrosis improvement 26% (30mg weekly) vs 7%. ENLIGHTEN Ph3: Results expected early 2027. |
Table 3: Preclinical Data (Models and Key Findings)
| Drug Name | Preclinical Model | Key Findings & Endpoints | Translational Accuracy |
|---|---|---|---|
| Resmetirom | GAN DIO-MASH Mouse | Improved NAS score ≥2, reduced liver TG/TC, decreased α-SMA expression (across all models), reduced Sirius Red area. | High: Highly concordant with clinical MASH resolution and fibrosis improvement rates. |
| Semaglutide | GAN DIO-MASH Mouse | Improved NAS score ≥2, weight loss 22%, significant improvement in steatosis/inflammation, decreased α-SMA. Fibrosis stage regression unclear. | Moderate: Predicted high MASH resolution. Clinical fibrosis improvement exceeded model expectations. |
| Lanifibranor | GAN DIO-MASH Mouse | Improved NAS score ≥2-3 (14/15 mice), weight loss 28.9%, the only compound confirming regression of fibrosis stages. | Very High: Clearly predicted potent, direct anti-fibrotic action. |
| Efruxifermin | db/db Mouse, STAM Model | Increased adiponectin, decreased PRO-C3, blood glucose reduction 30-60%. Improved fibrosis markers. | High: Accurately suggested long-term fibrosis improvement effects. |
References
Clinical Trial Registries (ClinicalTrials.gov)
- MAESTRO-NASH (Resmetirom): NCT03900429
- ESSENCE (Semaglutide): NCT04822181
- SYNERGY-NASH (Tirzepatide): NCT04166773
- Survodutide Ph2 MASH: NCT04771273
- LIVERAGE (Survodutide Ph3 F2-F3): NCT06632444
- LIVERAGE-Cirrhosis (Survodutide Ph3 F4): NCT06632457
- HARMONY (Efruxifermin F2-F3): NCT04767529
- SYMMETRY (Efruxifermin F4): NCT05039450
- SYNCHRONY Histology (Efruxifermin Ph3): NCT06215716
- SYNCHRONY Real-World (Efruxifermin Ph3): NCT06161571
- SYNCHRONY Outcomes (Efruxifermin Ph3 F4): NCT06528314
- NATIVE (Lanifibranor Ph2b): NCT03008070
- NATiV3 (Lanifibranor Ph3): NCT04849728
- FASCINATE-2 (Denifanstat): NCT05976230
- ENLIVEN (Pegozafermin Ph2b): NCT05006885
- ENLIGHTEN-Fibrosis (Pegozafermin Ph3): NCT05931887